DEC. 17, 2015@New York Times@
AstraZeneca to Acquire Majority Stake in
The British drug maker AstraZeneca said on Thursday that it had agreed to
acquire a majority stake in Acerta Pharma, a
privately held cancer-drug developer with operations in the Netherlands and in
California, for $4 billion.
The deal gives AstraZeneca the option to buy the remainder
of the company for $3 billion more and would further bolster its line of
Transactions in the health care sector have helped make 2015 a record year for
global mergers and acquisitions.
Drug makers have used mergers and strategic investments to acquire promising
treatments in late-stage development, hoping to claim the next blockbuster.
gThe investment is consistent with our focus on long-term growth and reflects
the role targeted business development plays in our business model,h Pascal
Soriot, the AstraZeneca chief executive, said in a news release about the Acerta
gWe are boosting a key area in our comprehensive oncology portfolio with a
late-stage, potential best-in-class medicine that could transform treatment for
patients across a range of blood cancers,h he added.
Under the terms of the deal, AstraZeneca would acquire a
55 percent stake in Acerta for an initial payment of $2.5 billion. It
would then pay $1.5 billion when
acalabrutinib, Acertafs treatment for blood cancer,
receives regulatory approval in the United States or by the end of 2018.
It would then have the option to buy the remainder of the company after the
approval of the drug in Europe and the United States, and other milestones.
AstraZeneca said that an extensive development program for acalabrutinib was
underway and that it may be able to take the first steps toward regulatory
approval of treating patients with certain types of blood cancer in the second
half of 2016.
The top yearly sales of the drug could exceed $5 billion globally, AstraZeneca
The deal came after AstraZeneca announced on Monday that the companies were
exploring gpotential strategic options.h
AstraZeneca has said it would target similar small or midsize deals as it looks
to bolster its drug pipeline after it fought off a $119
billion takeover bid by Pfizer last year, which would have created the
worldfs largest pharmaceutical company.
Pfizer ª AstraZenecaÉûñÄ
In November, AstraZeneca agreed to
acquire ZS Pharma, a California-based biopharmaceutical company, for $2.7
billion in cash.
This week, AstraZeneca also announced that it
would acquire the core respiratory
business of Takeda Pharmaceutical Company of Japan for $575 million.
WuXi AppTecÐ (NYSE: WXjÍQOOONPQÉÝ§³êAyÑAJð_Æ·éãòiE¶¨ãòiEãÃ@íÆ±ðæèµ¤¢ELÌóõïÐÅ·BZpvVå±^AÚquüÌïÐÆµÄA¾ÐÍnò¤yÑJvZXÉ¨¯éLÍÅ^ÌT[rXðñµÄ¢Ü·BRXgptH[}XÌÇ¢ø¦IÈeíÆ±óõð@ÉæèA¢EenÌ¨qlÌ¤JÔZkAãòiEãÃ@í¤Jïá¸ÌêÆÈéæ¤É¾ÐT[rXÍÝv³êÄ¢Ü·B
Sept. 10, 2012
MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic
for Chinese Market
MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, a
leading research and development outsourcing company, today announced that
they have formed a joint venture to develop and commercialize MEDI5117(©ÈÆu¾³ÆÇ«¾³Ép¢éVKÌ¶¨»Ü),
a novel biologic for autoimmune and inflammatory diseases, in China.
MedImmune will provide technical and development expertise, while WuXi
AppTec will provide local regulatory, manufacturing, pre-clinical and
clinical trial support. When undertaking clinical trial development in
China, the government requires local manufacture of medicines that have not
been approved in other markets.
2015N 12 16ú@
còiÌ\ÉæéÆAeEnæÅÌ³êÄ¢é¯ÌæÌ»iâ¡ÌOÕ°iKÉ é»¨àÚÇ³êéBÚÇÌ®¹É ½èAêèÌ]ÆõªAXg[lJÉÚÐ·éB
February 5 2015
Agreement strengthens AstraZenecafs
aclidinium respiratory franchise and adds immediate revenues with long-term
Actavis Plc today announced that they have entered into a definitive
agreement under which AstraZeneca will acquire the rights to Actavisf
branded respiratory business in the US and Canada for an initial
consideration of $600 million on completion and low single-digit royalties
above a certain revenue threshold.
Upon completion of the transaction,
AstraZeneca will own the development and commercial rights in the US and
Canada to TudorzaTM PressairTM (aclidinium bromide
inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA)
for chronic obstructive pulmonary disease (COPD), and
Daliresp® (roflumilast), the only once-daily oral PDE4 inhibitor
currently on the market for COPD. AstraZeneca will also own development
rights in the US and Canada for LAS40464, the combination of a fixed dose of
aclidinium with formoterol long acting beta agonist (LAMA/LABA) in a dry
powder inhaler, which is approved in the EU under the brand name Duaklir®